Ceftazidime therapy of serious bacterial infections.
Ceftazidime, a new broad-spectrum cephalosporin, was administered to 30 patients with serious bacterial infections in a randomized dosing trial with daily doses of 1.5 or 3 g. Both regimens were equally efficacious, with satisfactory clinical responses in 28 instances (93%) and microbiological eradication of 79% of initial bacterial isolates. The development of resistance to ceftazidime during therapy was observed in three cases (Enterobacter agglomerans, Enterobacter cloacae, and Pseudomonas aeruginosa) and superinfection by a resistant Enterobacter agglomerans strain occurred in one case. Adverse reactions of clinical significance included one case each of leukopenia, azotemia, diarrhea (Clostridium difficile toxin positive), and rash.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004754:Enterobacter / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011549:Pseudomonas / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects; D014511:Uremia / Q000139:chemically induced
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002442:Ceftazidime